Adjuvant sunitinib in renal cell carcinoma: from evidence to recommendation
Ann Oncol
.
2017 Apr 1;28(4):682-684.
doi: 10.1093/annonc/mdx014.
Author
A Bex
1
Affiliation
1
Department of Urology, The Netherlands Cancer Institute, Postbus, Amsterdam, The Netherlands.
PMID:
28104620
DOI:
10.1093/annonc/mdx014
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antineoplastic Agents
Carcinoma, Renal Cell*
Humans
Indoles
Kidney Neoplasms
Pyrroles*
Sunitinib
Substances
Antineoplastic Agents
Indoles
Pyrroles
Sunitinib